Company

GenSpera

As of the edition of 20 October 2026, GenSpera runs 1 drug; it is on route A at 3 targets and on route B at 0 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Stopped1
Total1

Where it needs a new molecule

Route A at 3 targets, route B at 0 targets.

Three of its 3 rows, by target and route
TargetRoute
ATP2A1 Sarcoplasmic/endoplasmic reticulum calcium ATPase 1Route A
ATP2A3 Sarcoplasmic/endoplasmic reticulum calcium ATPase 3Route A
ATP2A2 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2Route A

All 3 rows on route A or B

In the product

3 company-target rows on route A or B; 0 are not shown here, and no score is.

Where its trials are

  • Cancer: 6 trials led
  • Urinary and reproductive: 3 trials led
  • Digestive system: 1 trials led